[1]
|
Heit JA. The epidemiology of venous thromboembolism in the community[J]. Arterioscler Thromb Vasc Biol, 2008, 28:370-372. doi: 10.1161/ATVBAHA.108.162545 |
[2]
|
Schünemann HJ, Cook D, Guyatt G, et al.Methodology for antithrombotic and thrombolytic therapy guideline development:American College of Chest Physicians evidence-based clinical practice guidelines (8th ed)[J]. Chest, 2008, 133:113S-122S. doi: 10.1378/chest.08-0666 |
[3]
|
Guyatt GH, Eikelboom JW, Gould MK, et al. Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients:antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 Suppl):e185S-194S. http://www.onacademic.com/detail/journal_1000038942250310_d3e0.html |
[4]
|
吕厚山, 徐斌.人工关节置换术后下肢深静脉血栓形成[J].中华骨科杂志, 1999, 19:155-156. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgkzz98199903008 |
[5]
|
孙建行.创伤性下肢深静脉血栓形成的治疗探讨[J].中国中医骨伤科杂志, 2007, 15:6-8. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgzygsk200704002 |
[6]
|
中华医学会心血管病学分会肺血管病学组, 中国医师协会心血管内科医师分会.急性肺血栓栓塞症诊断治疗中国专家共识[J].中华内科杂志, 2010, 49:74-81. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk201001026 |
[7]
|
中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南(第二版)[J].中华外科杂志, 2012, 50:611-613. http://qikan.cqvip.com/Qikan/Article/Detail?id=1003027731 |
[8]
|
Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans[J]. Drug Metab Dispos, 2009, 37:74-81. doi: 10.1124/dmd.108.023143 |
[9]
|
Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4, 5, 6, 7-tetrahydro-1H-pyrazolo[3, 4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Ⅹa[J]. J Med Chem, 2007, 50:5339-5356. doi: 10.1021/jm070245n |
[10]
|
Buller H, Deitchman D, Prins M, et al.Efficacy and safety of the oral direct factor Ⅹa inhibitor apixaban for symptoma-tic deep vein thrombosis:the Botticelli DVT dose-ranging study[J]. J Thromb Haemost, 2008, 6:1313-1318. doi: 10.1111/j.1538-7836.2008.03054.x |
[11]
|
Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement[J]. N Engl J Med, 2009, 361:594-604. doi: 10.1056/NEJMoa0810773 |
[12]
|
Lassen MR, Raskob GE, Gallus A, et al. ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2):a randomised double-blind trial[J]. Lancet, 2010, 375:807-815. doi: 10.1016/S0140-6736(09)62125-5 |
[13]
|
Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients:antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 Suppl):e278S-325S. http://cid.oxfordjournals.org/external-ref?access_num=10.1378/chest.11-2296&link_type=DOI |
[14]
|
Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans[J]. Drug Metab Dispos, 2008, 36:386-399. doi: 10.1124/dmd.107.019083 |
[15]
|
Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:a randomised, double-blind, non-inferiority trial[J]. Lancet, 2007, 370:949-956. doi: 10.1016/S0140-6736(07)61445-7 |
[16]
|
Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:the RE-MODEL randomized trial[J]. J Thromb Haemost, 2007, 5:2178-2185. doi: 10.1111/j.1538-7836.2007.02748.x |
[17]
|
Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery[J]. J Arthroplasty, 2009, 24:1-9. doi: 10.1016/S0883-5403(08)00834-6 |
[18]
|
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism[J]. N Engl J Med, 2009, 361:2342-2352. http://gut.bmj.com/external-ref?access_num=10.1056/NEJMoa0906598&link_type=DOI |
[19]
|
Schulman S, Kakkar AK, Schellong S, et al.A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RECOVER Ⅱ)[J]. Blood, 2011, 118:205. |
[20]
|
Schulman S, Baanstra D, Eriksson H, et al.Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism[J]. J Thromb Haemost, 2011, 9:22. http://www.researchgate.net/publication/295663864_Dabigatran_vs_placebo_for_extended_maintenance_therapy_of_venous_thromboembolism |
[21]
|
Kubitza D, Becka M, Wensing G, et al.Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Ⅹa inhibitor-after multiple dosing in healthy male subjects[J]. Eur J Clin Pharmacol, 2005, 61:873-880. doi: 10.1007/s00228-005-0043-5 |
[22]
|
Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J]. N Engl J Med, 2008, 358:2765-2775. doi: 10.1056/NEJMoa0800374 |
[23]
|
Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a double-blind, randomised controlled trial[J]. Lancet, 2008, 372:31-39. doi: 10.1016/S0140-6736(08)60880-6 |
[24]
|
Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4):a randomised trial[J]. Lancet, 2009, 373:1673-1680. doi: 10.1016/S0140-6736(09)60734-0 |
[25]
|
Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J]. N Engl J Med, 2008, 358:2776-2786. doi: 10.1056/NEJMoa076016 |
[26]
|
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism[J]. N Engl J Med, 2010, 363:2499-2510. doi: 10.1056/NEJMoa1007903 |
[27]
|
EINSTEIN-PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J].N Engl J Med, 2012, 366:1287-1297. doi: 10.1056/NEJMoa1113572 |
[28]
|
Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism:the continued treatment study (EINSTEIN-extension study)[J]. Expert Rev Cardiovasc Ther, 2011, 9:841-844. doi: 10.1586/erc.11.62 |
[29]
|
Weitz JI, Bates SM. New anticoagulants[J]. J Thromb Haemost, 2005, 3:1843-1853. doi: 10.1111/j.1538-7836.2005.01374.x |
[30]
|
Samama MM, Le Flem L, Guinet C, et al. Comparative responses of some clotting assays to fondaparinux, dabigatran and rivaroxaban. 20th international congress on thrombosis, June 25-28, 2008[C]. Athens, Greece: [s.n.], 2008. |